notable that, within the same dosage range, these drugs in addition inhibit nonimmune inflammation, i.e. they are also anti-inflammatory in a conventional sense. Also, they are much more effective at preventing an immunological response than abrogating one already under way. Do they modify rheumatoid arthritis by suppressing immunity? Formal testing of treated patients has provided variable results; a number of investigators have found effectively treated patients to show no evidence of immune suppression (Currey 197Ib) , leading to speculation that these drugs may achieve their effect by a prolonged anti-inflammatory action. There is good evidence that both cyclophosphamide (Hurd & Ziff 1974) and azathioprine (Campbell et al. 1976 ) gradually deplete certain subpopulations of peripheral blood mononuclear cells, and it seems likely that this is a pointer to their mode of action.
The use of immunosuppressive drugs in rheumatoid arthritis raises the question whether in this disease there is a significant alteration in immune reactivity. No gross or consistent alterations have been demonstrated, but there has been speculation that autoimmune phenomena may arise because of a defect in T-cell suppressor function (Allison et al. 1971 ). There has thus been considerable interest in the report (Huskisson et af. 1976 ) that rheumatoid arthritis may respond to levamisole, an anthelminthic drug which also has the property of correcting defective immune responsiveness in certain disease states (Ramot et at. 1976 ). It appears to restore to normal the activity of phagocytic cells and lymphocytes involved in cell mediated immunity (Lima et al. 1974 , De Cree et al. 1974 ).
The response of rheumatoid patients to levamisole was gradual in onset, as with the other slow acting drugs such as gold, and the degree of improvement was comparable too.
These observations have led to speculation that some or all of the slow acting drugs may have a common mode of action; not immune suppression, but immune 'restoration' or 'modulation'.
In the case of levamisole Huskisson and his colleagues found some evidence that, in rheumatoid patients, there was some correlation between an increase in skin responsiveness to purified protein derivative and pain relief. Amongst the other slow acting drugs any such evidence is scanty, possibly because it has not been sought. We have noted that gold injections can accelerate the appearance of adjuvant arthritis in the rat (Jessop & Currey 1968), and antiproliferative drugs in small doses can enhance antibody responses in experimental animals (Chanmougan & Schwartz 1966) . Penicillamine can certainly produce marked immunological activity, including immune complex nephritis and other immune mediated diseases such as Goodpasture's syndrome, as well as stimulating the appearance of antinuclear antibodies (Harpey et al. 1971) .
There are thus a number of fragments of information which provide at least a talking point for the immune modulation hypothesis for the mechanism ofaction of the delayed action drugs in rheumatoid arthritis. The appeal of the hypothesis is that it opens up another therapeutic avenue to explore: that of developing a drug with activity like thymosine (thymic hormone). One approach that has already been tried is the administration of transfer factor, a cell-free dialysate of leukocytes able to transfer specific cell-mediated immunity from cell donor to recipient. In a small pilot study Natvig and his colleagues (1976) obtained encouraging results in three children with juvenile chronic polyarthritis.
